Tau
protein is found
in abundance in neurons of the central nervous system. This protein is a
product of microtubule-associated protein tau (MAPT) gene, that is located on
chromosome 17. It is associated with pathologies of several nervous system
disorders, such as dementia, Parkinson’s disease, and Alzheimer’s disease.
The main
function of the protein is to stabilize microtubules. There are six isoforms of
the protein present in the brain tissue which can be distinguished by their
number of binding domains. The advancements in the protein by hyperphosphorylation
and aggregation are observed in a molecular study of the disease.
Report Description:
AC Immune SA
is developing a number of tau proteins inhibitor molecules. Neurimmune Holding
AG is also in the process of developing BIIB076 as a tau protein inhibitor, for
the treatment of Alzheimer’s disease. ProMIS Neurosciences Inc. is another
company developing tau proteins.
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials. Pipeline analysis of drugs by phases includes
product description and development activities including information about
clinical results, designations, collaborations, licensing, grants, technology,
and others.
No comments:
Post a Comment